

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENT	iii
ENGLISH ABSTRACT	iv
THAI ABSTRACT	vi
LIST OF TABLES	x
LIST OF FIGURES	xi
ABBREVIATIONS	xiii
CHAPTER 1 INTRODUCTION	
1.1 ALLERGIC RHINITIS (AR)	2
1.1.1 Definition and classification of AR	2
1.1.2 Epidemiology	3
1.1.3 Risk factors for the development of AR	3
1.1.4 Pathophysiology of AR	5
1.1.5 Co-morbidities of AR	9
1.1.6 Diagnosis of AR	11
1.1.7 The management of AR	11
1.2 RHINOMANOMETRY	16
1.3 NASAL CYTOLOGY	18
1.4 BACKGROUND OF MEDICATIONS	22
1.5 HYPOTHESIS	24
1.6 PURPOSE OF THE STUDY	24
CHAPTER 2 METATERIALS AND METHODS	
2.1 STUDY DESIGN	25
2.2 PATIENT SELECTION	25
2.2.1 Number of patients	25
2.2.2 Inclusion criteria	26

2.2.3 Exclusion criteria	26
2.2.4 Withdrawal criteria	27
2.3 TREATMENT PROCEDURES	27
2.4 PROTOCOL OUTLINE	28
2.5 EFFICACY ASSESSMENT	33
2.6 SAFETY ASSESSMENT	33
2.7 ASSESSMENT OF PATIENT PREFERENCE OF TEST DRUGS	33
2.8 STATISTICAL ANALYSIS	35
 CHAPTER 3 RESULTS	
3.1 PATIENT CHARACTERISTICS	36
3.2 SKIN PRICK TEST	39
3.3 SUBJECTIVE ASSESSMENT	39
3.3.1 Total nasal symptom scores (TNSSs)	39
3.3.2 Total ocular symptom scores (TOSSs)	43
3.4 OBJECTIVE ASSESSMENT	45
3.4.1 Nasal airway resistance (NAR)	45
3.4.2 Nasal cytology	47
3.5 ASSESSMENT OF PATIENT PREFERENCE	50
3.6 ASSESSMENT OF ADVERSE EVENTS	53
3.7 ASSESSMENT OF USE OF RESCUE THERAPY	54
 CHAPTER 4 DISCUSSION AND CONCLUSION	
4.1 DISCUSSION	55
4.2 CONCLUSION	61
 REFERENCES	62
 VITA	75


LIST OF TABLES

Table	Page
1 Assessment of patient preference questionnaire items	34
2 Patient characteristics and baseline data	38
3 Baseline data presented with TOSSs and mean percentage of the cell types	38
4 Effects of MF and FF on TNSSs and the individual symptom scores before and after 2 and 4 weeks of treatment	40
5 Effects of MF and FF on TOSSs and the individual symptom scores before and after 2 and 4 weeks of treatment	43
6 Effect of MF and FF on unilateral and total NAR (Pa/cm ³ /s) before and after 2 and 4 weeks of treatment	45
7 Effects of MF and FF on inflammatory cell before and after 2 and 4 weeks of treatment	47
8 Effects of MF and FF attributes on patient preference after 2 and 4 weeks of treatment	51
9 AEs in MF and FF treatment groups	53
10 Use of rescue therapy of MF and FF groups	54

LIST OF FIGURES

Figure	Page
1 Classification of AR according to WHO's ARIA guidelines	3
2 Diagrammatic representation of pressure-flow curve during a breath	17
3 Structural formulae of FF and MF with 17-furoate ester group	23
4 Diagram illustrates the protocol procedure of the study	29
5 ATMOS rhinomanometer PC300	32
6 Position of patient for active anterior RMM	32
7 Flow chart of patient randomization and withdrawn	37
8 Mean change from baseline of TNSs and the individual symptom scores after 2 weeks of treatment	41
9 Mean change from baseline of TNSs and the individual symptom scores after 4 weeks of treatment	41
10 The number of responders in MF and FF treatment groups	42
11 Mean change from baseline of TOSSs and the individual symptom scores after 2 weeks of treatment	44
12 Mean change from baseline of TOSSs and the individual symptom scores after 4 weeks of treatment	44
13 Mean change from baseline in unilateral and total NAR ($\text{Pa}/\text{cm}^3/\text{s}$) after 2 weeks of treatment at 75 and 150 Pa; and after 4 weeks of treatment at 75 and 150 Pa	46
14 Mean percent change from baseline of inflammatory cells after 2 weeks of treatment	48
15 Mean percent change from baseline of inflammatory cells after 4 weeks of treatment	48
16 Percent of patients with increase or decrease in eosinophils, neutrophils and basophils at the end of week 4 treatment compared with pretreatment	49

17 Effects of MF and FF attributes on patient preference after 4 weeks of treatment	52
18 Percentage of patients very satisfied and satisfied with MF and FF treatment after 4 weeks of treatment	52




ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved

ABBREVIATIONS

AU/mL	=	arbitrary unit per milliliter
cm ³ /s	=	cubic centimeter per second
h	=	hour
μg	=	microgram
μL	=	microliter
mg	=	milligram
mL	=	milliliter
min	=	minute
Pa	=	Pascal
Pa/ cm ³ /s	=	Pascal per cubic centimeter per second
PNU/mL	=	protein nitrogen unit per mililiter
sec	=	second
W/V	=	weight per volume
AEs	=	adverse events
ANOVA	=	analysis of variances
AP-1	=	activator protein-1
APC	=	antigen-presenting cells
AR	=	allergic rhinitis
ARIA	=	Allergic Rhinitis and its Impact on Asthma
BDP	=	beclomethasone dipropionate
BUD	=	budesonide
CGRP	=	calcitonin gene-related peptide
CYP450	=	cytochrome P450
ECP	=	eosinophil cationic protein
EDN	=	eosinophil-derived neurotoxin
FF	=	fluticasone furoate
FP	=	fluticasone propionate

GM-CSF	=	granulocyte macrophage colony stimulating factor
GR	=	glucocorticoid receptors
HLA	=	human leukocyte antigen
HPA	=	hypothalamic–pituitary–adrenal
IAR	=	intermittent allergic rhinitis
ICAM-1	=	intercellular adhesion molecule-1
IFN	=	interferon
IgE	=	immunoglobulin E
IL	=	interleukin
INCs	=	intranasal corticosteroids
ITT	=	intention to treat
LTs	=	leukotrienes
LTRAs	=	leukotriene receptor antagonists
MBP	=	major basic protein
MEE	=	middle ear effusion
MF	=	mometasone furoate
MHC	=	major histocompatibility complex
NAR	=	nasal airway resistance
NF- κ B	=	nuclear factor kappa B
NK	=	neurokinin
NSS	=	normal saline
PAR	=	perennial allergic rhinitis
PER	=	persistent allergic rhinitis
PG	=	prostaglandin
PM	=	particulate matter
PMN	=	polymorphonuclear
QOL	=	quality of life
RANTES	=	regulated upon activation normal T cell expressed and secreted
RMM	=	rhinomanometry
RRA	=	relative receptor affinity



SAR	=	seasonal allergic rhinitis
SD	=	standard deviation
SEM	=	standard error of the mean
SP	=	substance P
SPT	=	skin prick test
TGF	=	transforming growth factor
Th	=	T helper
TNSSs	=	total nasal symptom scores
TNF	=	tumor necrosis factor
TOSSs	=	total ocular symptom scores
VCAM-1	=	vascular cell adhesion molecule-1
VIP	=	vasoactive intestinal peptide
WHO	=	World Health Organization

ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่

Copyright© by Chiang Mai University
All rights reserved